The immunotherapy of prostate cancer
Advanced prostate cancer remains incurable with standard treatment options. Immunotherapy may be a realistic alternative given the growing evidence that the immune response can affect the growth of other solid tumours and the regulation of both specific and shared prostate cancer antigens. Early stu...
Gespeichert in:
| Veröffentlicht in: | Prostate cancer and prostatic diseases 2000-12, Vol.3 (4), p.303-307 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 307 |
|---|---|
| container_issue | 4 |
| container_start_page | 303 |
| container_title | Prostate cancer and prostatic diseases |
| container_volume | 3 |
| creator | Dalgleish, A G Perry, M J A Eaton, J D Hrouda, D Todryk, S M Kirby, R S |
| description | Advanced prostate cancer remains incurable with standard treatment options. Immunotherapy may be a realistic alternative given the growing evidence that the immune response can affect the growth of other solid tumours and the regulation of both specific and shared prostate cancer antigens. Early studies suggest that both non-specific and specific vaccines can effect relevant animal models and clinical trials based on these observations are now in progress. A number of other approaches including gene therapy with HSVtk are already undergoing clinical studies (Herman et al. Hum Gene Ther 1999; 10: 1239-1249). Prostate Cancer and Prostatic Diseases (2000) 3, 303-307 |
| doi_str_mv | 10.1038/sj.pcan.4500487 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902330737</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2645322049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-5b1561f0af21b5eb00e381bdf03646341a65fb25a7be3ab5ee13bea16e8b65453</originalsourceid><addsrcrecordid>eNp9kc1LAzEQxYMotlbP3qSooJdtJ5l87VGKX1DwUs8h2WZpl-6Hm91D_3tTuiAIepo5_OY95j1CrinMKKCeh2LWZLaacQHAtTohY8qVTIQEfRp3lCJRWrARuQihAICUpnBORpTxVIHGMblfbfx0W5Z9VXcb39pmP63zadPWobOdn0btzLeX5Cy3u-Cvhjkhny_Pq8Vbsvx4fV88LZMMleoS4aiQNAebM-qEdwAeNXXrHFByiZxaKXLHhFXOo42Ep-i8pdJrJwUXOCEPR93o_9X70JlyGzK_29nK130wKTBEUKgi-fgvSbVIUWuMP07I3S-0qPu2in8YJqMpY8DTSN3-SbEUYoaKRWh-hLKYT2h9bpp2W9p2byiYQx8mFObQhxn6iBc3g2zvSr_-4YcC8BtEdYQj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229085272</pqid></control><display><type>article</type><title>The immunotherapy of prostate cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Dalgleish, A G ; Perry, M J A ; Eaton, J D ; Hrouda, D ; Todryk, S M ; Kirby, R S</creator><creatorcontrib>Dalgleish, A G ; Perry, M J A ; Eaton, J D ; Hrouda, D ; Todryk, S M ; Kirby, R S</creatorcontrib><description>Advanced prostate cancer remains incurable with standard treatment options. Immunotherapy may be a realistic alternative given the growing evidence that the immune response can affect the growth of other solid tumours and the regulation of both specific and shared prostate cancer antigens. Early studies suggest that both non-specific and specific vaccines can effect relevant animal models and clinical trials based on these observations are now in progress. A number of other approaches including gene therapy with HSVtk are already undergoing clinical studies (Herman et al. Hum Gene Ther 1999; 10: 1239-1249). Prostate Cancer and Prostatic Diseases (2000) 3, 303-307</description><identifier>ISSN: 1365-7852</identifier><identifier>EISSN: 1476-5608</identifier><identifier>DOI: 10.1038/sj.pcan.4500487</identifier><identifier>PMID: 12497083</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Animal models ; Antigens ; Cancer vaccines ; Clinical trials ; Gene therapy ; Immune response ; Immune system ; Immunotherapy ; Prostate cancer ; Solid tumors ; Tumors ; Vaccines</subject><ispartof>Prostate cancer and prostatic diseases, 2000-12, Vol.3 (4), p.303-307</ispartof><rights>Copyright Nature Publishing Group Dec 2000</rights><rights>Macmillan Publishers Limited 2000.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12497083$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dalgleish, A G</creatorcontrib><creatorcontrib>Perry, M J A</creatorcontrib><creatorcontrib>Eaton, J D</creatorcontrib><creatorcontrib>Hrouda, D</creatorcontrib><creatorcontrib>Todryk, S M</creatorcontrib><creatorcontrib>Kirby, R S</creatorcontrib><title>The immunotherapy of prostate cancer</title><title>Prostate cancer and prostatic diseases</title><addtitle>Prostate Cancer Prostatic Dis</addtitle><description>Advanced prostate cancer remains incurable with standard treatment options. Immunotherapy may be a realistic alternative given the growing evidence that the immune response can affect the growth of other solid tumours and the regulation of both specific and shared prostate cancer antigens. Early studies suggest that both non-specific and specific vaccines can effect relevant animal models and clinical trials based on these observations are now in progress. A number of other approaches including gene therapy with HSVtk are already undergoing clinical studies (Herman et al. Hum Gene Ther 1999; 10: 1239-1249). Prostate Cancer and Prostatic Diseases (2000) 3, 303-307</description><subject>Animal models</subject><subject>Antigens</subject><subject>Cancer vaccines</subject><subject>Clinical trials</subject><subject>Gene therapy</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Prostate cancer</subject><subject>Solid tumors</subject><subject>Tumors</subject><subject>Vaccines</subject><issn>1365-7852</issn><issn>1476-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kc1LAzEQxYMotlbP3qSooJdtJ5l87VGKX1DwUs8h2WZpl-6Hm91D_3tTuiAIepo5_OY95j1CrinMKKCeh2LWZLaacQHAtTohY8qVTIQEfRp3lCJRWrARuQihAICUpnBORpTxVIHGMblfbfx0W5Z9VXcb39pmP63zadPWobOdn0btzLeX5Cy3u-Cvhjkhny_Pq8Vbsvx4fV88LZMMleoS4aiQNAebM-qEdwAeNXXrHFByiZxaKXLHhFXOo42Ep-i8pdJrJwUXOCEPR93o_9X70JlyGzK_29nK130wKTBEUKgi-fgvSbVIUWuMP07I3S-0qPu2in8YJqMpY8DTSN3-SbEUYoaKRWh-hLKYT2h9bpp2W9p2byiYQx8mFObQhxn6iBc3g2zvSr_-4YcC8BtEdYQj</recordid><startdate>200012</startdate><enddate>200012</enddate><creator>Dalgleish, A G</creator><creator>Perry, M J A</creator><creator>Eaton, J D</creator><creator>Hrouda, D</creator><creator>Todryk, S M</creator><creator>Kirby, R S</creator><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7T5</scope></search><sort><creationdate>200012</creationdate><title>The immunotherapy of prostate cancer</title><author>Dalgleish, A G ; Perry, M J A ; Eaton, J D ; Hrouda, D ; Todryk, S M ; Kirby, R S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-5b1561f0af21b5eb00e381bdf03646341a65fb25a7be3ab5ee13bea16e8b65453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animal models</topic><topic>Antigens</topic><topic>Cancer vaccines</topic><topic>Clinical trials</topic><topic>Gene therapy</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Prostate cancer</topic><topic>Solid tumors</topic><topic>Tumors</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dalgleish, A G</creatorcontrib><creatorcontrib>Perry, M J A</creatorcontrib><creatorcontrib>Eaton, J D</creatorcontrib><creatorcontrib>Hrouda, D</creatorcontrib><creatorcontrib>Todryk, S M</creatorcontrib><creatorcontrib>Kirby, R S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><jtitle>Prostate cancer and prostatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dalgleish, A G</au><au>Perry, M J A</au><au>Eaton, J D</au><au>Hrouda, D</au><au>Todryk, S M</au><au>Kirby, R S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The immunotherapy of prostate cancer</atitle><jtitle>Prostate cancer and prostatic diseases</jtitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><date>2000-12</date><risdate>2000</risdate><volume>3</volume><issue>4</issue><spage>303</spage><epage>307</epage><pages>303-307</pages><issn>1365-7852</issn><eissn>1476-5608</eissn><abstract>Advanced prostate cancer remains incurable with standard treatment options. Immunotherapy may be a realistic alternative given the growing evidence that the immune response can affect the growth of other solid tumours and the regulation of both specific and shared prostate cancer antigens. Early studies suggest that both non-specific and specific vaccines can effect relevant animal models and clinical trials based on these observations are now in progress. A number of other approaches including gene therapy with HSVtk are already undergoing clinical studies (Herman et al. Hum Gene Ther 1999; 10: 1239-1249). Prostate Cancer and Prostatic Diseases (2000) 3, 303-307</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>12497083</pmid><doi>10.1038/sj.pcan.4500487</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-7852 |
| ispartof | Prostate cancer and prostatic diseases, 2000-12, Vol.3 (4), p.303-307 |
| issn | 1365-7852 1476-5608 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902330737 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | Animal models Antigens Cancer vaccines Clinical trials Gene therapy Immune response Immune system Immunotherapy Prostate cancer Solid tumors Tumors Vaccines |
| title | The immunotherapy of prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T06%3A50%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20immunotherapy%20of%20prostate%20cancer&rft.jtitle=Prostate%20cancer%20and%20prostatic%20diseases&rft.au=Dalgleish,%20A%20G&rft.date=2000-12&rft.volume=3&rft.issue=4&rft.spage=303&rft.epage=307&rft.pages=303-307&rft.issn=1365-7852&rft.eissn=1476-5608&rft_id=info:doi/10.1038/sj.pcan.4500487&rft_dat=%3Cproquest_cross%3E2645322049%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229085272&rft_id=info:pmid/12497083&rfr_iscdi=true |